[{"id":"2add9cbf-45b6-4ca2-b88c-b9bfd4516d3a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05007418","created_at":"2021-08-16T16:54:44.805Z","updated_at":"2024-07-02T16:35:57.559Z","phase":"Phase 1b","brief_title":"Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma","source_id_and_acronym":"NCT05007418","lead_sponsor":"Sorrento Therapeutics, Inc.","biomarkers":" CD38","pipe":" | ","alterations":" CD38 expression","tags":["CD38"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e STI-1492"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 10/01/2022","start_date":" 10/01/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2023-01-16"}]